Gene expression library

Horizon Discovery has introduced Edit-R CRISPRa arrayed CRISPR RNA (crRNA) libraries, the latest addition to its CRISPR activation (CRISPRa) reagent platform from the recently acquired Dharmacon business. The new libraries offer a powerful tool for drug discovery, pathway analysis and disease progression studies.

Unlike lentiviral pooled screens, Edit-R synthetic crRNA arrayed libraries enable one-gene-per-well investigation, using high-content assays to answer more in-depth biological questions. A CRISPRa-based system for overexpression studies also overcomes many of the shortcomings of early generations of DNA plasmid-encoded gene expression tools. By triggering the endogenous gene’s expression, the gene is transcribed in its native form, so researchers can be assured of highly relevant results in their cell system.

The Edit-R CRISPRa portfolio includes catalogue libraries for popular human and mouse gene families, such as ubiquitin enzymes, transcription factors, and kinases, in addition to drug-targeted genes and the whole human genome. Bespoke collections are also available to support researchers working with a specialised gene target list.

More information on Horizon’s CRISPRa reagents and screening services is available online.

www.horizondiscovery.com/research-services/functional-genomicscreening/crispr-screening

 

 

Other news

Upcoming Events

British Society for Haematology 59th Annual Scientific Meeting

SEC Glasgow
1-3 April 2019

Focus 2019

SEC Glasgow
1-3 May 2019

Respiratory Microbiology - A Day of Inspiration

Royal Air Force Museum, Hendon
16 May 2019

Clinical and Laboratory Haemostasis 2019

The Atrium Conference Centre, Sheffield Hallam University
5-6 June 2019

The Oxford Haematology in Obstetrics Postgraduate Course

St Edmund Hall, Queen's Lane, Oxford OX1 4AR
9-11 September 2019

Latest Issue

Pathology In Practice

Pathology In Practice

Feb 2019

Early disease detection: a collaborative approach

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.